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Mass deworming to improve developmental health and 
wellbeing of children in low-income and middle-income 
countries: a systematic review and network meta-analysis
Vivian A Welch, Elizabeth Ghogomu, Alomgir Hossain, Shally Awasthi, Zulﬁ qar A Bhutta, Chisa Cumberbatch, Robert Fletcher, Jessie McGowan, 
Shari Krishnaratne, Elizabeth Kristjansson, Salim Sohani, Shalini Suresh, Peter Tugwell, Howard White*, George A Wells*
Summary
Background Soil-transmitted helminthiasis and schistosomiasis, considered among the neglected tropical diseases by 
WHO, aﬀ ect more than a third of the world’s population, with varying intensity of infection. We aimed to evaluate the 
eﬀ ects of mass deworming for soil-transmitted helminths (with or without deworming for schistosomiasis or co-
interventions) on growth, educational achievement, cognition, school attendance, quality of life, and adverse eﬀ ects 
in children in endemic helminth areas.
Methods We searched 11 databases up to Jan 14, 2016, websites and trial registers, contacted authors, and reviewed 
reference lists. We included studies published in any language of children aged 6 months to 16 years, with mass 
deworming for soil-transmitted helminths or schistosomiasis (alone or in combination with other interventions) for 
4 months or longer, that reported the primary outcomes of interest. We included randomised and quasi-randomised 
trials, controlled before–after studies, interrupted time series, and quasi-experimental studies. We screened in 
duplicate, then extracted data and appraised risk of bias in duplicate with a pre-tested form. We conducted random-
eﬀ ects meta-analysis and Bayesian network meta-analysis.
Findings We included 52 studies of duration 5 years or less with 1 108 541 children, and four long-term studies 
8–10 years after mass deworming programmes with more than 160 000 children. Overall risk of bias was moderate. 
Mass deworming for soil-transmitted helminths compared with controls led to little to no improvement in weight over 
a period of about 12 months (0·99 kg, 95% credible interval [CrI] −0·09 to 0·28; moderate certainty evidence) or height 
(0·07 cm, 95% CrI −0·10 to 0·24; moderate certainty evidence), little to no diﬀ erence in proportion stunted (eight fewer 
per 1000 children, 95% CrI −48 to 32; high certainty evidence), cognition measured by short-term attention (−0·23 points 
on a 100 point scale, 95% CI −0·56 to 0·14; high certainty evidence), school attendance (1% higher, 95% CI −1 to 3; 
high certainty evidence), or mortality (one fewer per 1000 children, 95% CI −3 to 1; high certainty evidence). We found 
no data on quality of life and little evidence of adverse eﬀ ects. Mass deworming for schistosomiasis might slightly 
increase weight (0·41 kg, 95% CrI −0·20 to 0·91) and has little to no eﬀ ect on height (low certainty evidence) and 
cognition (moderate certainty evidence). Our analyses do not suggest indirect beneﬁ ts for untreated children from 
being exposed to treated children in the community. We are uncertain about eﬀ ects on long-term economic productivity 
(hours worked), cognition, literacy, and school enrolment owing to very low certainty evidence. Results were consistent 
across sensitivity and subgroup analyses by age, worm prevalence, baseline nutritional status, infection status, impact 
on worms, infection intensity, types of worms (ascaris, hookworm, or trichuris), risk of bias, cluster versus individual 
trials, compliance, and attrition.
Interpretation Mass deworming for soil-transmitted helminths with or without deworming for schistosomiasis had 
little eﬀ ect. For schistosomiasis, mass deworming might be eﬀ ective for weight but is probably ineﬀ ective for height, 
cognition, and attendance. Future research should assess which subset of children do beneﬁ t from mass deworming, 
if any, using individual participant data meta-analysis.
Funding Canadian Institutes of Health Research and WHO. 
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
WHO recommends mass deworming for soil-transmitted 
helminths and schistosomiasis in endemic areas, 
combined with improved sanitation and health education 
to sustain the eﬀ ects and reduce reinfection.1 Mass 
deworming of children has been described as the most 
cost-eﬀ ective strategy to improve educational attendance 
in endemic helminth countries.2 Although deworming is 
inexpensive (US$0·50) per child,3 the global cost of 
implementing the WHO recom mendations for all 
children is estimated to be $276 million annually.4
A 2015 Cochrane review5 concluded that mass 
deworming does not improve child health or school 
performance; however, concerns have been raised that 
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the review did not suﬃ  ciently address a number of 
methodological issues that might have inﬂ uenced its 
conclusions.6–10 Children older than 3 years who are 
stunted might not be able to catch up on growth.6 
Interaction with food, micronutrients, hygiene 
promotion, or other deworming drugs such as 
praziquantel for schistosomiasis might inﬂ uence 
eﬀ ectiveness.7 Outcome measures for attendance need 
to be considered in light of validity of on-site versus 
school records.7 The types of worms, their prevalence, 
and appropriateness and intensity of deworming drugs 
for each worm type need to be considered, as does eﬀ ect 
dilution due to uninfected or lightly infected children in 
the sample.6 Poor learning environments might 
contribute to little eﬀ ects on cog nition. Long-term study 
designs need to be considered.9,10 Finally, analysis of 
mass deworming needs to consider the possibility of 
indirect spill-over eﬀ ects: untreated children might 
beneﬁ t from exposure to treated children in the same 
classroom or neighbourhood because of reduced worm 
burden. Thus, indirect eﬀ ects could dilute eﬀ ects in 
individually randomised trials, making cluster trials 
more suitable to assess the eﬀ ectiveness of mass 
deworming.7
We aimed to evaluate the eﬀ ects of the WHO policy 
on deworming for soil-transmitted helminths and 
schistosomiasis on growth, cognition, educational 
achievement, school attendance, wellbeing, and adverse 
eﬀ ects, with or without other co-interventions, in children 
in endemic helminth countries. We also addressed the 
concerns about previous reviews.
Methods
Search strategy and selection criteria
We did a systematic review using a causal pathway 
approach, following an a priori protocol11 (ﬁ gure 1). We 
chose to use both meta-analysis and network meta-analysis, 
which allowed us to compare eﬀ ectiveness of interventions 
that were not compared directly (eg, food, micronutrients, 
and drug combinations). We used methods described in 
the Cochrane Handbook and the ISPOR guidelines for 
network meta-analyses.12 Our report is guided by the 
PRISMA Statement for Network Meta-Analyses.13
We developed a comprehensive search strategy with 
our information scientist (JM) for electronic databases 
and grey literature; this strategy was reviewed with 
PRESS (Peer Reviewed Electronic Search Strategies)14 by 
the information scientist of the Campbell International 
Development Group. We searched 11 databases up to 
Jan 14, 2016, with no language restrictions. We also 
searched websites of relevant organisations, Twitter 
(#wormwars), screened reference lists, and used 
SCOPUS to identify studies which cited included 
studies.14 We contacted authors for information missing 
from their original papers. Search strategy details can be 
found in the appendix (pp 5–6).
Studies had to include mass administration of any 
drug for chemoprevention of soil-transmitted helminths 
or schistosomiasis alone or in combination with other 
deworming drugs or other interventions compared with 
placebo or other interventions in children aged 6 months 
to 16 years with no other demographical restrictions. To 
assess eﬀ ects in infected children, we expanded our 
See Online for appendix
Research in context
Evidence before this study
Previous systematic reviews on mass deworming for 
soil-transmitted helminths disagree regarding important 
eﬀ ects for weight and haemoglobin. An updated Cochrane 
review in 2015 found little to no eﬀ ect on haemoglobin, 
growth, cognition, education, attendance, and mortality. 
Nonetheless, concerns were raised that this Cochrane review 
did not consider explanatory factors such as type of worm and 
baseline nutritional status.
Added value of this study
Our systematic review and network meta-analysis provides new 
insights into mass deworming for soil-transmitted helminths by 
taking the following ten factors into account: reinfection; role of 
baseline nutritional status; that uninfected children in studies 
might dilute the eﬀ ects; that only heavily infected children are 
aﬀ ected by worms; possibility of diﬀ erent eﬀ ects by worm type; 
combinations with co-interventions of hygiene, micronutrients, 
and other drugs; long-term studies following up to 10 years 
later; spill-over eﬀ ects on untreated children across studies; 
inﬂ uence of poor learning environments on cognition; and 
quality of school attendance measures. We found little to no 
eﬀ ect of mass deworming for soil-transmitted helminths with 
or without deworming for schistosomiasis on growth, 
short-term attention, cognitive development, attendance, 
school achievement, and mortality. Overall, our analyses do not 
support causal pathway assumptions about inﬂ uence of mass 
deworming on child health and school performance. 
For long-term eﬀ ects on growth, educational outcomes, and 
school attendance, our certainty in the evidence is very low. 
Mass deworming for schistosomiasis might improve weight, 
might have little to no eﬀ ect on height (low certainty), probably 
has little to no eﬀ ect on cognition and attendance (moderate 
certainty), and has uncertain eﬀ ects on school enrolment (very 
low certainty evidence).
Implications of all the available evidence
Our analyses are based on aggregate level data, which might 
hide diﬀ erences in eﬀ ects at the individual level or interaction 
between factors. Given over 1 million children have been 
randomised to mass deworming in these previous studies, 
future research should take advantage of individual participant 
data from these studies to assess in which populations and 
settings—if any—mass deworming is beneﬁ cial. 
For the Cochrane Handbook see 
http://handbook.cochrane.org/
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protocol’s eligibility criteria to include studies that 
screened for infection. We included randomised and 
quasi-randomised trials, controlled before–after studies, 
interrupted time series studies, and quasi-experimental 
designs that used methods to account for confounding 
and sample selection bias. Studies had to include one or 
more of the primary outcomes of growth, cognition, 
school achievement, school attendance, or adverse 
eﬀ ects. Studies had to be at least 4 months’ duration, 
because we considered this the minimum timeframe for 
diﬀ erences in our primary outcomes.11
We also collected data on haemoglobin, micronutrient 
status, hygiene practices, worm burden, and other 
comorbidities; costs and resource use, health equity, and 
process elements such as how and where drugs were 
delivered; supervision, compliance, and attrition.
Data extraction
VAW and EG independently screened titles and 
abstracts, then assessed full-text articles for eligibility 
and extracted data and assessed risk of bias using a 
pretested form. We contacted authors for additional 
information (appendix p 33). We assessed bias using 
the Cochrane risk of bias tool. For quasi-experimental 
studies, we used the International Development 
Coordinating Group’s risk of bias tool.15 We rated the 
certainty of evidence using the GRADE methods for 
network meta-analysis16 and pairwise meta-analysis.17 
GRADE certainty is deﬁ ned as “the extent of 
our conﬁ dence that the estimates of the eﬀ ect are 
correct”.17 Disagreements were resolved by consensus 
or discussion with a third reviewer, PT.
Statistical analysis
For the continuous outcomes of growth, the eﬀ ect size of 
weight (kg) and weight-for-age (WAZ) was analysed as 
standardised mean diﬀ erences of change from baseline, 
using Cohen’s d, because this increased our sample for 
exploring heterogeneity more than if we had used either 
weight or WAZ alone. We also did this for height (cm) 
and height-for-age (HAZ). Eﬀ ect sizes for other outcomes, 
such as weight-for-height, haemoglobin, cognition, 
school achievement (math and language), and school 
attendance, were analysed as changes from baseline, as 
planned in our protocol.11 We calculated the SD of the 
change from baseline using a correlation coeﬃ  cient of 
0·9 for weight, height, and haemoglobin and 0·71 for 
cognition, based on published studies.18,19 We used end 
values if only end values were available. We used the 
variance inﬂ ation factor to adjust for unit of analysis 
issues, based on intraclass correlations from included 
studies. For cognition, we analysed short-term attention, 
general intelligence, and development separately.
We did the primary analyses using randomised 
and quasi-randomised trials because we considered 
randomised trials at lower risk of bias. The eﬀ ects of 
interventions in controlled before–after studies were 
assessed separately, and were not included in network 
meta-analyses (except for sensitivity analysis).
We did two levels of analysis: ﬁ rst, meta-analyses of 
all outcomes for each comparison; and second, network 
meta-analysis. For the meta-analyses we used Review 
Manager 5.3, and assessed heterogeneity for each 
comparison using visual inspection and statistical 
methods (χ² test and I²). We explored heterogeneity 
Figure 1: Logic model showing causal pathways
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using inﬂ uence analysis, subgroup, and sensitivity 
analyses. We conducted Bayesian network meta-
analysis using WinBUGS20 according to the routine 
that accommodates multiarm trials.21 Consistency 
between direct and indirect evidence was formally 
assessed using back-calculation and node-splitting 
techniques.22 We used model diagnostics including 
trace plots and the Brooks-Gelman-Rubin statistic to 
assess and ensure model convergence. In each network 
meta-analysis, parameter estimates were obtained 
based on three chains using 80 000 iterations after a 
burn-in of 40 000 iterations for the random-eﬀ ects 
model.
We did pre-speciﬁ ed subgroup analysis across age, 
nutritional status, prevalence of worms, and sex. These 
subgroup analyses were done using both network meta-
analysis and meta-analysis. We assessed indirect eﬀ ects 
on untreated children using three methods: assessment 
of within-study analyses; comparison of control group 
gains in weight, height, and haemoglobin in cluster and 
individually randomised trials; and comparison of 
eﬀ ects in cluster versus individually randomised trials. 
Although meta-regressions were planned, data was 
insuﬃ  cient. Therefore, we assessed the relationship of 
weight, height, and attendance with prevalence of each 
worm (ascaris, hookworm, and trichuris) and impact on 
each type of worm using weighted least-squares 
regression. To explore the causal pathway, we also 
assessed the relationship between attendance outcomes 
and weight gain. We did pre-planned sensitivity analyses 
to assess the impact of two studies excluded because of 
baseline imbalance,23 risk of bias, type of worm, impact 
on worm burden, intensity, and study design. We did 
post-hoc sensitivity analyses to assess the inﬂ uence of 
cutoﬀ  thresholds for worm prevalence, impact on 
worms, and nutritional status. We assessed the 
inﬂ uence of including studies that screened for 
infection as a sensitivity analysis. Publication bias was 
assessed with funnel plots when we had more than 
ten studies.
Missing values were not imputed for trials. For studies 
for which we received full datasets, we assumed data 
were not missing at random; therefore, we used the 
Cochrane Handbook guidance to impute missing data, 
based on available data, last observation carried forward 
for one trial, and single imputation for the other. We 
assessed the inﬂ uence of using imputed values with 
sensitivity analyses.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. VAW, EG, SS, GAW, and AH had 
full access to all the data in the study and VAW had 
ﬁ nal responsibility for the decision to submit for 
publication. This study is registered with the Campbell 
Collaboration.11
Figure 2: Study selection
CBA=controlled before-after study. cRCT=cluster randomised controlled trial.
13 136 records screened after duplicates removed
413 full-text articles assessed for eligibility
12 723 records excluded on the basis of title and 
 abstract
320 full-text articles excluded
 147 all had children infected with no relevant 
  outcomes
 62 without relevant outcomes
 18 too short (<4 months)
 47 not a study
 14 deworming in all arms
3 pending studies
 2 ongoing RCTs
 1 ongoing CBA
56 studies included, from 75 
 articles 
 33 RCTs
 14 cRCTs
 5 CBAs
 4 long-term studies
14 studies that screened for 
 infection, from 15 articles
 8 RCTs
 1 cRCT
 4 CBAs
 1 long-term study
Interventions Total sample size 
(participants in 
each arm)
Duration (months) Mean age or 
age range 
(years)
Treatment Follow-up
Albendazole standard (2 doses per year)
Alderman, 
2006*
Albendazole vs control 27 995
(14940/13055)
36 ·· 3·7
Awasthi, 
2000
Albendazole vs placebo 1061
(451/610)
24 ·· 2·7
Bhoite, 2012 Albendazole vs albendazole plus 
iron vs control
496
(128/215/153)
8 6 8–12
Dossa, 2001 Albendazole vs albendazole plus 
iron vs iron vs placebo
140
(38/34/36/32)
13 ·· 3–5
Fox, 2005 Albendazole vs albendazole plus 
diethylcarbamazine vs 
diethylcarbamazine vs placebo
1292
(328/324/322/318)
6 ·· 7·7
Hadju, 1997 Albendazole vs pyrantel vs 
albendazole LF vs pyrantel LF 
vs placebo
330
(69/61/66/60/74)
12 ·· 8·3
Kruger, 1996 Albendazole plus non-fortiﬁ ed 
soup vs albendazole plus 
iron-fortiﬁ ed soup vs iron-fortiﬁ ed 
soup plus placebo vs non-fortiﬁ ed 
soup plus placebo
178
(37/50/54/37)
6 5 6–8
Monse, 2013 Albendazole vs health education 412
(200/212)
48 ·· 7·5
Olds, 1999 Albendazole vs praziquantel vs 
albendazole plus praziquantel 
vs placebo
1540
(387/380/392/381)
12 ·· 10·5
Rozelle, 2015 Albendazole plus health education 
vs control
2179
(1084/1095)
12 ·· 10·6
(Table continues on next page)
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Results
The search retrieved 13 136 unique articles (appendix 
pp 5–6). We included 47 randomised trials and 
ﬁ ve controlled before–after studies, which included 
1 108 541 children (ﬁ gure 2, table). We found no eligible 
interrupted time series studies. We included four long-
term studies, which collectively followed up more than 
160 000 children.24–27 We received and included additional 
data from ten studies, including two unpublished 
studies. We used the corrected dataset for the 
Kenya Primary School Deworming Project.28,29 Three 
unpublished studies are pending publication.
The median age of children was 6·75 years (range 0–18). 
The studies were in schools, clinics, and communities. 
Prevalence of ascaris, trichuris, and hookworm ranged 
from 1% to 95%. None of the studies of mass deworming 
excluded children on the basis of intensity of infection. 
No studies reported on the learning environment. Overall 
risk of bias was moderate, with 40% of studies with high 
risk of bias for diﬀ erential attrition and more than 50% 
of studies with insuﬃ  cient details to assess blinding 
(ﬁ gure 3). Risk of bias for long-term studies was high or 
moderate. Funnel plots did not suggest publication bias 
(appendix p 85).
The network geometry was chosen through discussion 
with the clinicians and policy maker members of the 
team regarding what was sensible to combine from a 
clinical and policy perspective. Network meta-analyses 
for weight (30 trials), height (25 trials), weight-for-height 
(12 trials), and proportion stunted (seven trials) converged 
and were consistent. We present meta-analysis only for 
attendance, short-term cognition, cognitive development, 
mathematical achievement, and mortality, due to too few 
studies or failure to converge. For weight, height, and 
stunting, meta-analysis and network meta-analysis 
results were consistent (appendix pp 37–56).
Based on our primary analyses and summary of 
ﬁ ndings table (appendix pp 64–71), mass deworming for 
soil-transmitted helminths with albendazole twice per 
year compared with controls probably leads to little to 
no improvement in weight over a period of about 
12 months (0·09 kg, 95% credible intervals [CrI] 
−0·09 to 0·28; moderate certainty evidence) or height 
(0·07 cm, 95% CrI −0·10 to 0·24; moderate certainty 
evidence), little to no diﬀ erence in weight-for-height 
(SD 0·14, 95% CrI −0·20 to 0·49; high certainty 
evidence), proportion stunted (eight fewer per 
1000 children, 95% CrI −48 to 32; high certainty 
evidence), performance on short-term attention tasks 
(unlikely to be inﬂ uenced by the learning environments; 
−0·23 points on a 100 point scale, 95% CI −0·56 to 0·14; 
high certainty evidence), school attendance (1%, 
95% CI −1 to 3; high certainty evidence), or mortality 
(one fewer per 1000 children, 95% CI −3 to 1; high 
certainty evidence). 12 trials with insuﬃ  cient data and 
ﬁ ve controlled before–after studies were consistent with 
these analyses. Eﬀ ects of mass deworming for 
soil-transmitted helminths on long-term (>8 years) eco-
nomic productivity (hours worked), school enrolment, 
Interventions Total sample size 
(participants in 
each arm)
Duration (months) Mean age or 
age range 
(years)
Treatment Follow-up
(Continued from previous page)
Stephenson, 
1993
Albendazole vs albendazole LF 
vs placebo
284
(95/96/93)
8·2 ·· 10·6
Sur, 2005 Albendazole vs placebo 702
(351/351)
12 ·· 2–5
Miguel, 
2004*
Albendazole vs albendazole plus 
praziquantel vs control
>30 000† 3 ·· 6–18
Watkins, 
1996
Albendazole vs placebo 227
(116/111)
6 ·· 7–12
Albendazole high (>2 doses per year)
Ndibazza, 
2012
Albendazole HF vs placebo 2016
(1010/1006)
45 ·· 1·25–5
Wiria,
2013
Albendazole HF vs placebo 4004
(2022/1982)
21 ·· 5–15
Albendazole low (<2 doses per year)
Beach,
1999
Albendazole LF vs ivermectin 
vs albendazole LF plus ivermectin 
vs placebo
958
(244/240/245/229)
4 ·· 7·4
Stephenson, 
1989
Albendazole LF vs placebo 150
(78/72)
6 ·· 6–16
Koroma, 
1996
Albendazole LF vs placebo 297
(197/100)
6 ·· 6–10
Albendazole standard (2 doses per year) plus praziquantel standard (2 doses per year)
Taylor, 2001 Albendazole plus praziquantel 
vs albendazole plus praziquantel 
plus iron vs albendazole HF plus 
praziquantel plus iron 
vs albendazole HF plus 
praziquantel vs iron vs placebo
428 
(60/56/63/57/101/91)
12 ·· 11·2
Albendazole standard (2 doses per year) plus praziquantel low (1 dose per year)
Jinabhai, 
2001a
Albendazole plus praziquantel LF 
vs placebo
268 (129/139) 4 ·· 8–10
Albendazole low (1 dose per year) plus praziquantel low (1 dose per year) plus biscuits with vitamin A, iron, 
and nutrients
Jinabhai, 
2001b
Albendazole LF plus praziquantel 
LF plus multi-micronutrient 
fortiﬁ ed biscuits vs 
multi-micronutrient fortiﬁ ed 
biscuits vs albendazole LF plus 
praziquantel LF plus non-fortiﬁ ed 
biscuits vs vitamin-A-fortiﬁ ed 
biscuits vs non-fortiﬁ ed biscuits
579† 4 ·· 9·1
Albendazole standard (2 doses per year) plus fortiﬁ ed beverage
Solon, 2003 Albendazole plus 
micronutrient-fortiﬁ ed beverage vs 
micronutrient-fortiﬁ ed beverage vs 
albendazole plus non-fortiﬁ ed 
beverage vs non-fortiﬁ ed beverage 
plus placebo
831 
(203/209/213/206)
4 ·· 9·9
Albendazole high (>2 doses per year) plus iron
Bobonis, 
2006
Albendazole HF plus iron 
vs control
2392
(930/1462)
11 ·· 3·65
(Table continues on next page)
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height, and cognition are unclear owing to very low 
certainty evidence (appendix p 63).24–27 Adverse eﬀ ects 
were minimal for mass deworming with albendazole 
(moderate certainty evidence). No studies reported cases 
of intestinal obstruction. Two studies found eﬀ ects of 
deworming were not sustained once deworming was 
stopped (moderate certainty evidence).
We found little to no diﬀ erence between any mass 
deworming treatments for soil-transmitted helminths 
compared with each other, diﬀ erent frequencies of 
treatment, or between deworming combined with 
micronutrients or food (ﬁ gure 4, appendix p 62).
Mass deworming for schistosomiasis alone might 
slightly increase weight (0·41 kg, 95% CrI −0·20 to 0·91), 
lead to little to no increase in height (−0·02 cm, 95% CrI 
−0·43 to 0·40; low certainty evidence), little to no eﬀ ect 
on short-term attention (high certainty evidence), and 
uncertain eﬀ ects on school enrolment owing to very low 
certainty evidence (appendix pp 69–71).25
Indirect eﬀ ects on untreated children were assessed in 
two studies28,30 with conﬂ icting results. One cluster trial,28 
reanalysed by an external team,29 found a within-school 
indirect eﬀ ect of 5·6% (SE 2·0) for attendance and 18% 
(SE 7·0) for hookworm infection and between-school 
indirect eﬀ ects for distances between 0 km and 6 km of 
−1·7% (SE 3·0) for attendance and 15% (SE 11·0) for 
hookworm infection. These estimates were challenged 
by the original authors, who calculated post hoc that 
between-school indirect eﬀ ects for attendance were 
statistically signiﬁ cant and important up to 4 km.31 
Another cluster trial30 found small, non-signiﬁ cant 
indirect eﬀ ects for weight and attendance. Indirect 
eﬀ ects assessed across included studies showed no 
beneﬁ t to control children in individually randomised 
trials compared with cluster trials for weight, height, 
haemoglobin, attendance, or worm burden. These 
analyses had high heterogeneity (I² reported in appendix 
p 64). Sensitivity analyses using cluster trials only 
(indirect eﬀ ects are expected to be smaller due to distance 
between clusters) were consistent with our main results 
of little to no eﬀ ect on weight, height, or attendance 
(appendix p 77, 80, 83) and the test for subgroup 
diﬀ erences compared with individually randomised 
trials was not signiﬁ cant (appendix p 64).
Considering health equity, all of the studies were in 
very poor settings and found few eﬀ ects of mass 
deworming. One trial30 found increased eﬀ ects of 
deworming on preschool attendance for children with 
mothers with less than 3 years education (median) 
compared with mothers with 3 or more years education 
(low certainty evidence). We are uncertain about the 
inﬂ uence of poverty on eﬀ ects of deworming on long-
term mathematical skills and literacy27 (very low certainty 
evidence). No other studies assessed eﬀ ects across 
socioeconomic status.
Contamination from external sources of deworming 
was reported only in two cluster trials,28,32 in which 
Interventions Total sample size 
(participants in 
each arm)
Duration (months) Mean age or 
age range 
(years)
Treatment Follow-up
(Continued from previous page)
Nga,
2009
Albendazole HF plus 
multi-micronutrient fortiﬁ ed 
biscuits vs albendazole HF plus 
non-fortiﬁ ed biscuits vs 
multi-micronutrient fortiﬁ ed 
biscuits vs non-fortiﬁ ed biscuits 
plus placebo
510 
(127/127/128/128)
4 ·· 6–8
Albendazole standard (2 doses per year) plus vitamin A
Awasthi, 
2001
Albendazole plus vitamin A 
vs vitamin A
2010
(988/1022)
18 ·· 9·6
Awasthi, 
2008
Albendazole plus vitamin A 
vs vitamin A
3935
(1968/1967)
24 ·· 1–5
Awasthi, 
2013
Albendazole plus vitamin A 
vs vitamin A
1 000 000† 60 ·· 0·5–6
Hall,
2006
Albendazole plus vitamin A 
vs placebo plus vitamin A
2659
(1341/1318)
24 ·· 6·8
Levamisole high (>2 doses per year)
Willett, 1979 Levamisole vs placebo 341 (166/175) 12 ·· 3·2
Mebendazole standard (2 doses per year)
Kloetzel, 
1982
Mebendazole vs placebo 337 (165/172) 10 ·· 1–8
Garg,
2002
Mebendazole vs placebo 370 (177/193) 6·5 ·· 2–4
Joseph,
2015
Mebendazole vs mebendazole LF 
plus placebo vs placebo plus 
mebendazole LF vs placebo
1760 
(440/440/440/440)
12 ·· 1
Stoltzfus, 
1997
Mebendazole vs mebendazole HF 
vs control
3605 
(1170/1175/1260)
12 ·· 10
Mebendazole standard (2 doses per year) plus iron
Ebenezer, 
2013
Mebendazole plus iron vs placebo 1621 (813/808) 6 6 9·5
Le Huong, 
2007
Mebendazole plus non-fortiﬁ ed 
noodles vs mebendazole plus 
iron-fortiﬁ ed noodles vs 
mebendazole plus iron vs 
iron-fortiﬁ ed noodles plus 
placebo vs non-fortiﬁ ed noodles 
plus placebo
425 
(84/85/84/88/84)
6 ·· 7·2
Mebendazole high (>2 doses per year)
Donnen, 
1998
Mebendazole HF vs vitamin A 
vs control
358
(123/118/117)
18 ·· 1·9
Kaba,
1978
Mebendazole HF vs levamisole HF 
vs mebendazole HF plus 
levamisole HF
176 (44/45/87) 15 ·· 6–11
Ostwald, 
1984
Mebendazole HF vs control 87 (42/45) 5 ·· 7–10
Rousham, 
1994b
Mebendazole HF vs placebo 1402 (688/714) 12 ·· 3·9
Stoltzfus, 
2001
Mebendazole HF vs mebendazole 
HF plus iron vs iron vs placebo
614† 12 ·· 2·4
Mebendazole high plus pyrantel high (>2 doses per year)
Lai,
1995
Mebendazole HF plus pyrantel HF 
vs placebo
353 (186/167) 24 ·· 7·5
(Table continues on next page)
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34% and 5% of control children accessed deworming, 
respectively.
Subgroup analyses found no clinically important or 
statistically signiﬁ cant eﬀ ects across age (<2 years, 
2–5 years, and >5 years), prevalence (high, moderate, 
low), or proportion of children stunted (<30 vs ≥30% with 
HAZ of −2) for weight, height, or attendance. Results 
were consistent for all prevalence cutoﬀ s from 10–90% 
and all cutoﬀ s for proportion of children stunted (from 
10–60% of population with HAZ ≤−2), suggesting 
dilution of eﬀ ect by non-infected children does not 
explain the small eﬀ ects (appendix pp 86–92). Subgroup 
analyses within included studies agreed with these 
ﬁ ndings, with three exceptions. Within-study analyses 
suggest no diﬀ erence in eﬀ ect of mass deworming 
between boys and girls for weight and height. Two 
studies28,30 found larger eﬀ ects on attendance for girls 
than for boys (low certainty evidence). We are uncertain 
whether mass deworming has diﬀ erent eﬀ ects for men 
and women on long-term years of education or hours 
worked in the past week because of very low certainty 
evidence (appendix p 66).24
Mass deworming was, on average, eﬀ ective at reducing 
burden of all worms by comparison with placebo, but 
eﬀ ect sizes were highly variable, from 98% risk reduction 
to 54% increase for some comparisons (appendix p 73). 
Our weighted least-squares regression found no 
relationship between baseline ascaris, hookworm, or 
trichuris, or impact on these worms (assessed as relative 
risk reduction of each worm type, and which provides an 
indication of reinfection and possible dilution of eﬀ ect 
with uninfected children) and eﬀ ects on weight, height, 
or attendance (appendix pp 93–98).
Sensitivity analyses were consistent with primary 
analyses across diﬀ erent types of worms (≥50% ascaris or 
≥50% hookworm), cluster trials compared with 
individually randomised trials, studies with ≥50% relative 
risk reduction of worm burden, low risk of bias for 
allocation concealment, treatment of infected children 
only, more than 30% of children with moderate to heavy 
intensity of infection, lower intraclass correlation values, 
exclusion of unpublished studies, prevalence of schisto-
somiasis, studies with more than 75% compliance, and 
studies with less than 2% diﬀ erential attrition. We found 
increased eﬀ ects for weight and height in an inﬂ uence 
analysis when two studies with baseline imbalance were 
included in sensitivity analysis. Eﬀ ects on school 
attendance were greater with on-site records than with 
teacher records. Measures with on-site methods were at 
risk of bias because of inadequate blinding of both 
personnel and participants (in contrast to the other 
studies, which used school records to monitor attendance 
that had low or unclear risk of bias for blinding). 
(appendix pp 77–84).
We conducted sensitivity analyses to compare mass 
deworming with studies that screened for infection. 
Tests for subgroup diﬀ erences were not signiﬁ cant for 
weight, height, short-term attention, or attendance, with 
two exceptions. Treatment of children infected with 
schistosomiasis increased weight gain by 1·1 kg 
(95% CI 0·6–1·5) compared with mass deworming 
eﬀ ect of 0·14 kg (95% CI −0·16 to 0·42; test for subgroup 
diﬀ erences p=0·0009), but not height. Treatment of 
children infected with soil-transmitted helminths 
increased weight gain by 0·49 kg (95% CI 0·07–0·90) 
compared with mass deworming eﬀ ect of 0·04 kg 
(95% CI 0·00–0·10; test for subgroup diﬀ erences 
p=0·04), but not height. Over the long term, screening 
Interventions Total sample size 
(participants in 
each arm)
Duration (months) Mean age or 
age range 
(years)
Treatment Follow-up
(Continued from previous page)
Nutrition Enhancement Programme (1 dose per year)
Linnemayr, 
2011
Unspeciﬁ ed deworming plus 
vitamin A plus iron plus growth 
promotion plus bed nets plus 
cooking workshops
4296
(2321/1975)
32·4 ·· 0–3
Piperazine standard (2 doses per year)
Greenberg, 
1981
Piperazine vs placebo 185 (92/93) 11 ·· 1·5–8
Piperazine high (>2 doses per year)
Gupta,
1982
Piperazine HF vs metronidazole vs 
piperazine HF plus metronidazole 
vs placebo
159
(39/40/41/39)
12 ·· 2–5·1
Praziquantel (1 dose per year)
Makamu, 
2016
Praziquantel vs control 37 385
(4177/33 208)
120 ·· 7–14
Pyrantel high (>2 doses per year)
Pust,
1985
Pyrantel HF vs palm oil vs pyrantel 
HF plus palm oil vs placebo
789
(80/317/92/300)
12 ·· 1–4·5
Secnidazole (>2 doses per year)
Goto,
2009
Secnidazole vs albendazole plus 
secnidazole vs placebo
410
(141/142/127)
9 ·· 0·25–1·25
Tetrachloroethylene (1 doses per year)
Michaelsen, 
1985
Tetrachloroethylene vs placebo 228 (114/114) 5 ·· 5–7
Tetramisole standard (2 doses per year)
Reddy,
1986
Tetramisole vs tetramisole plus 
vitamin A vs vitamin A vs placebo
360
(75/116/108/61)
12 ·· 1–5
Tetramisole low (<2 doses per year)
Shah,
1975
Tetramisole LF vs iron-folic acid 325 (165/160) 12 ·· 1–5
Tetramisole high (>2 doses per year)
Gupta,
1977
Tetramisole HF vs placebo 154 (74/80) 12 ·· 0·5–2
Tiabendazole high (>2 doses per year)
Gateﬀ ,
1972
Tiabendazole HF vs placebo 392 (196/196) 8 ·· 6–15
HF=high frequency. LF=low frequency. Years followed by a or b refer to separate articles. References in the appendix. 
*Miguel, 2004 has two long-term follow-up studies (Ozier, 2015 and Baird, 2016), and Alderman, 2006 has 
one long-term follow-up study (Croke, 2014). †Exact numbers per group not reported. 
Table: Characteristics of included studies
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and treatment of infected children combined with 
sanitation improvements (eg, latrine building) leads to 
increased school enrolment, attendance, and improved 
literacy based on  the Rockefeller Hookworm eradication 
campaign33 (moderate certainty evidence). Whether 
mass deworming alone would have these eﬀ ects without 
the intensive sanitation interventions is very uncertain.
Discussion
Our review provides novel insight into mass deworming 
by taking into account ten criticisms of the Cochrane 
review: reinfection; the inﬂ uence of poor learning 
environments on cognition; combinations with co-
interventions of hygiene, micronutrients, and other 
drugs; long-term studies; indirect eﬀ ects on untreated 
children across studies; role of baseline nutritional 
status; that uninfected children in studies might dilute 
the eﬀ ects; possibility of diﬀ erent eﬀ ects by worm type; 
quality of school attendance measures; and that only 
heavily infected children are aﬀ ected by worms. With 
consideration of these criticisms, we found little to no 
eﬀ ect of mass deworming for soil-transmitted helminths 
with or without deworming for schistosomiasis on 
growth, short-term attention, cognitive development, 
attendance, school achievement, and mortality. Overall, 
our analyses do not support causal pathway assumptions 
about inﬂ uence of mass deworming on child health and 
school performance (ﬁ gure 1).
Our ﬁ ndings are in line with a Cochrane review5 of 
mass deworming for soil-transmitted helminths that 
found little to no eﬀ ect for all primary outcomes, even 
though diﬀ erent approaches were used in our 
systematic review to explore potential eﬀ ect modiﬁ ers 
and methodological concerns and 31 additional studies 
were included. These ﬁ ndings disagree with another 
review,34 which found important eﬀ ects of mass 
deworming on growth. This discrepancy might be 
because eight trials have since found little to no eﬀ ect 
of mass deworming on weight or height, alongside 
other methodological reasons described in the 
Cochrane review.5
To our knowledge, our review is the ﬁ rst to assess 
mass deworming for schistosomiasis. Mass deworming 
for schistosomiasis might slightly improve weight but 
has little to no eﬀ ect on height (low certainty), and 
probably has little to no eﬀ ect on cognition and 
attendance (moderate certainty). We are uncertain about 
eﬀ ects on school enrolment owing to very low certainty 
evidence.25 Treatment for children infected with 
schistosomiasis improved weight but not height (low 
certainty evidence).
The strengths of our review are that we conducted a 
comprehensive search, identiﬁ ed additional studies, and 
we found no evidence of publication bias. Furthermore, 
we reduced bias by using transparent methods, an a 
priori protocol, duplicate study selection, extraction, data 
entry, and cross-checking of data and results. We made 
several methodological decisions and tested the inﬂ uence 
of each of these using sensitivity analyses, and all were 
consistent with our main analyses. We used multiple 
approaches to assess the relationship of eﬀ ects to 
presumed eﬀ ect modiﬁ ers that strengthen our 
conclusions. We also used network meta-analysis, which 
provides added information on eﬀ ects of diﬀ erent 
frequencies and combinations of interventions (both 
drug and non-drug).
The limitations of our review are that the analysis 
of relationships between explanatory variables and 
outcomes should be interpreted with caution owing to 
non-normal data and few data points for attendance. 
However, these analyses were supported by sensitivity 
analyses exploring the inﬂ uence of cutoﬀ  thresholds. 
Subgroup and sensitivity analyses are based on aggregate 
level data, which might hide diﬀ erences in eﬀ ects at the 
individual level or interaction between factors.
We conducted an extensive assessment of eﬀ ect 
modiﬁ cation of mass deworming, and found little to no 
eﬀ ects of mass deworming for soil-transmitted 
helminths with or without deworming for schisto-
somiasis at the aggregate level. Two moderate quality 
long-term studies showed an increase in economic 
productivity (hours worked) and educational enrolment 
10 years after deworming.24,33 But it is uncertain whether 
these eﬀ ects are due to deworming or the combined 
sanitation and hygiene intervention. Mass deworming 
for schistosomiasis might slightly improve weight and 
probably has little to no eﬀ ect on height, cognition, and 
attendance. This independent analysis reinforces the 
case against mass deworming. These ﬁ ndings suggest 
that in addition to a reconsideration of mass deworming 
programmes in their current form, additional policy 
options need to be explored to improve child health and 
nutrition in worm-endemic areas. These policy options 
Figure 3: Risk of bias graph
Review authors’ judgments about each risk of bias item presented as percentages across all included studies. 
*Unit analysis errors in cluster randomised trials was judged as high risk of bias.
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Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of personnel
Blinding of participants
Blinding of outcome assessment (detection bias)
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include the need for investment in interventions to 
address basic determinants of worm infestations such 
as poverty, living conditions, sanitation, and inequities. 
Decisions on public health approaches in such settings 
need to be taken on the basis of human rights, 
ethics, and evidence-based, sustainable cost-eﬀ ective 
approaches. For schisto somiasis, policy implications are 
that mass deworming might be eﬀ ective at improving 
weight. Because all analyses of eﬀ ect modiﬁ cation are 
limited by aggregate level data which might hide 
individual level diﬀ erences, we propose that future 
research should assess which subset of children do 
beneﬁ t from mass deworming, if any, using individual 
patient data meta-analysis.
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Figure 4: Network meta-analysis and pairwise meta-analyses for primary outcomes, showing comparability of pairwise and network meta-analyses, as well 
as comparability in size of eﬀ ects for single deworming agents, and combinations with other drugs and agents
SMD=standardised mean diﬀ erence. NMA=network meta-analysis. RR=relative risk. HF=high frequency. *Cluster trial.
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